Company profile

23andMe, Inc.

23andMe, Inc. has 1 AI-enabled medical device on the FDA list. The first decision was on April 6, 2017 and the most recent on April 6, 2017 (23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia). Its most common review panel is Immunology (1 device).

1AI devices
2017First decision
2017Latest decision
1Specialties

Timeline

  1. 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia · Immunology · PTA